Royal Fund Management’s Teladoc Health TDOC Stock Holding History

Royal Fund Management’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-334	Closed	-$18K	–	654
2019 Q1	$18K	Hold	334	–	–	0.01%	315
2018 Q4	$16K	Hold	334	–	–	0.01%	294
2018 Q3	$28K	Buy	+334	New	+$23.8K	0.01%	242

Other funds holding TDOC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Royal Fund Management's TDOC Position: Q2 2019 in Review

Royal Fund Management sold out of Teladoc Health (TDOC) in Q2 2019, closing a stake of 334 shares — an estimated $18K sold.

Royal Fund Management first reported a position in TDOC in Q3 2018 and held it in 3 quarters. The position peaked at $28K in Q3 2018. 371 funds tracked by Wall St. Rank hold TDOC as of Q2 2019.

Royal Fund Management reported no remaining Teladoc Health position as of Q2 2019 after selling out during the quarter.
Royal Fund Management sold 334 Teladoc Health shares in Q2 2019, an estimated $18K.
Royal Fund Management first reported a position in Teladoc Health in Q3 2018 and held it in 3 quarters.
Royal Fund Management's Teladoc Health position peaked at $28K in Q3 2018.
371 funds tracked by Wall St. Rank held Teladoc Health as of Q2 2019.

Based on Royal Fund Management's 13F filing for Q2 2019, filed 8 May 2020.